Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference. A recording of the session is available below.
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is … selection, target engagement, safety assessments, and the advancement of ProQR's RNA editing therapies into and during …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in and Cambridge, Massachusetts, USA. In addition to our global presence, ProQR operates through a … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is … Biostatistics, you will provide senior statistical leadership across clinical and translational programs. This …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is … Development team and to provide scientific and strategic leadership for the nonclinical safety assessment of our …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is … supporting researchers and cross-functional teams in adopting high-quality data standards throughout the data …
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief